Faes Farma licences bilastines marketing rights in Indonesia to Kalbe

14 November 2011

Spanish drugmaker Faes Farma has signed a licence agreement for the commercialization of its antihistamine bilastine (trade name Bilastina) in Indonesia with that country’s largest pharmaceutical firm Kalbe Pharma. Financial terms were not disclosed.

The Indonesian pharmaceutical market is one of the major emerging markets in Asia with annual growth rates between 12% and 15.5% during the last four years in a country with 230 million people, the companies noted.
Kalbe Pharma is the largest publicly listed pharmaceutical company in Southeast Asia leading the Indonesian pharmaceutical market with a share of 13% in prescription drugs and of 14% in over-the-counter products.
Bilastine is a latest generation antihistaminic, indicated for the symptomatic treatment of allergic rhinoconjuntivitis and urticaria, with a rapid onset, long- lasting action and a wide safety profile.

Current bilastine licensees

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK